Affiliation Correction
In the original publication [1], there was an error regarding the affiliation 2, the correct affiliation should be “Oncologia Medica, IRCCS Foundation Ospedale Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy”.
Error in Table
There were some typographical errors in Table 1. The results of the CAVE mCRC (lines 9, 10 and 11 of Table 1) were not correctly reported. The corrected Table 1 appears below.
Table 1.
Completed rechallenge studies.
Table 1.
Completed rechallenge studies.
| Study | Study Type | Number of Patients | Rechallenge Treatment | RR | mPFS | mOS |
|---|---|---|---|---|---|---|
| Santini et al., 2012 [11] | Retrospective | 39 | FOLFIRI + Cetuximab Irinotecan + Cetuximab | 53.8% | 6.6 m | NR |
| CRICKET | Prospective | 28 | Irinotecan + Cetuximab | 21.4% | 3.4 m | 9.8 |
| CRICKET (RAS ctDNA WT) | Prospective | 13 | Irinotecan + Cetuximab | 31% | 4 m | 12.5 m |
| CRICKET (RAS ctDNA MUT) | Prospective | 12 | Irinotecan + Cetuximab | 0% | 1.9 m | 5.2 m |
| Sunakawa Y et al., 2020 [13] | Prospective | 16 | Irinotecan + anti-EGFR | 0% | 3.1 m | 8.9 m |
| Sunakawa Y et al., 2020 (RAS ctDNA WT) [13] | Prospective | 10 | Irinotecan + anti-EGFR | 0% | 4.7 m | 16 m |
| Sunakawa Y et al., 2020 (RAS ctDNA MUT) [13] | Prospective | 6 | Irinotecan + anti-EGFR | 0% | 2.3 m | 3.8 m |
| CAVE | Prospective | 77 | Cetuximab + Avelumab | 7.8% | 3.6 m | 13.1 m |
| CAVE (RAS/BRAF/ EGFR ctDNA WT) | Prospective | 48 | Cetuximab + Avelumab | 8.5% | 4.3 m | 16.3 m |
| CAVE (RAS/BRAF/ EGFR ctDNA MUT) | Prospective | 19 | Cetuximab + Avelumab | 5.1% | 3 m | 11.5 m |
| JACCRO CC-08 | Prospective | 34 | Irinotecan + Cetuximab | 0% | 2.4 m | 8.1 m |
| Liu X et al., 2015 [38] | Retrospective | 89 | Cetuximab ± Erlotinib | NR | 4.9 m (prior responder) 2.5 m (no responder) | NR |
| Tanioka H et al., 2018 [39] | Retrospective | 14 | Irinotecan + Cetuximab | 21.4% | 4.4 m | NR |
| Rossini D et al., 2020 [40] | Retrospective | 86 | Panitumumab/Cetuximab/FOLFIRI + Cetuximab/ FOLFOX + Panitumumab/CapIRI + Cetuximab/Irinotecan + Panitumumab/ Irinotecan + Cetuximab | 19.8% | 3.8 m | 10.2 m |
| Karani A et al., 2020 [42] | Retrospective | 17 | Cetuximab ± CT | 18% | 3.3 m | 8.4 m |
| Chong L et al., 2020 [43] | Retrospective | 22 | Cetuximab/Panitumumab | 4.5% | 4.1 m | 7.7 m |
RR: Response rate; mPFS: median progression free survival; mOS: median overall survival; m: Months; NR: Not reported; ctDNA: circulating tumor DNA; WT: Wild type; MUT: Mutant; EGFR: Epidermal growth factor receptor; CT: Chemotherapy.
In Table 2, information regarding the FIRE-4 (NCT02934529) clinical trial was not correctly reported. The corrected Table 2 appears below.
Table 2.
Rechallenge with anti-epidermal growth factor ongoing trials.
Table 2.
Rechallenge with anti-epidermal growth factor ongoing trials.
| Study Name | Phase | Number of Patient | Treatment Strategy | Liquid Biopsy Selection |
|---|---|---|---|---|
| VELO | II | 112 | Trifluridine/tipiracil + Panitumumab vs. Trifluridine/tipiracil | No |
| PARERE | II | 220 | Panitumumab > Regorafenib vs. Regorafenib > Panitumumab | Yes |
| PULSE | II | 120 | Panitumumab vs. Trifluridine/tipiracil or Regorafenib | Yes |
| FIRE-4 | III | 550 | I line FOLFIRI + Cetuximab II line FOLFOX + Bevacizumab III Irinotecan + Cetuximab vs. Regorafenib or another anti-EGFR free treatment | No |
| A-REPEAT | II | 33 | FOLFIRI/FOLFOX + Panitumumab | No |
| NCT03524820 | II | 60 | I line anti-EGFR + chemotherapy II line chemotherapy III line Cetuximab ± chemotherapy | No |
| CHRONOS | II | 27 | I line anti-EGFR + chemotherapy II line chemotherapy III line Panitumumab | Yes |
| CAPRI II GOIM | II | 200 | I line FOLFIRI + Cetuximab II Line FOLFOX + Cetuximab vs. FOLFOX + Bevacizumab III line Irinotecan + Cetuximab vs. Trifluridine/tipiracil or Regorafenib | Yes |
EGFR, epidermal growth factor receptor; /:OR.
Text Correction
1. There was a typing error in the original paper, all “Trifluoridine” should be changed to “Trifluridine”.
2. There was also an error regarding information about the FIRE4 clinical trial, specifically the number of patients included in the study and the primary endpoint. In the fourth paragraph on page 8, the original sentences read as follows:
“FIRE4 is a randomized phase II study including 230 patients with RAS WT mCRC and has the aim to evaluate irinotecan plus cetuximab vs. SOC as third-line therapy in patients with RAS WT mCRC, that have been treated with FOLFIRI plus cetuximab at first line (obtaining CR/PR with PFS >6 months) and after disease progression have received FOLFOX plus bevacizumab as second line treatment. The primary endpoint is OS.”
These should be changed to the following:
“FIRE4 is a randomized phase III study including 550 patients with RAS WT mCRC to evaluate irinotecan plus cetuximab vs. regorafenib or another anti-EGFR free treatment as a third-line therapy in patients with RAS WT mCRC. These patients were treated with FOLFIRI plus cetuximab at as a first-line treatment (obtaining CR/PR with PFS >6 months) and after disease progression received FOLFOX plus bevacizumab as a second-line treatment (NCT02934529). The primary endpoint was OS from randomization to third-line treatment. In OS3, patients responded to treatment with cetuximab under a cetuximab rechallenge vs. an anti-EGFR-free treatment.”
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.
Reference
- Ciardiello, D.; Martini, G.; Famiglietti, V.; Napolitano, S.; De Falco, V.; Troiani, T.; Latiano, T.P.; Ros, J.; Elez Fernandez, E.; Vitiello, P.P.; et al. Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).